Published in final edited form as:

J Med Chem. 2015 October 22; 58(20): 7959–7971. doi:10.1021/acs.jmedchem.5b00727.

Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu₁), Based on an *N*-(3-Chloro-4-(1,3-dioxoisindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu₁ Receptors Found in Schizophrenics

Pedro M. Garcia-Barrantes^{†,‡}, Hyekyung P. Cho^{†,‡}, Colleen M. Niswender^{†,‡}, Frank W. Byers^{†,‡}, Charles W. Locuson^{†,‡}, Anna L. Blobaum^{†,‡}, Zixiu Xiang^{†,‡}, Jerri M. Rook^{†,‡}, P. Jeffrey Conn^{†,‡}, and Craig W. Lindsley^{*,†,‡,§}

[†]Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6600, United States

[‡]Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6600, United States

[§]Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232-6600, United States

Abstract

The therapeutic potential of selective mGlu₁ activation is vastly unexplored relative to the other group I mGlu receptor, mGlu₅; therefore, our lab has focused considerable effort toward developing mGlu₁ positive allosteric modulators (PAMs) suitable as in vivo proof of concept tool compounds. Optimization of a series of mGlu₁ PAMs based on an *N*-(3-chloro-4-(1,3-dioxoisindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide scaffold provided **17e**, a potent (mGlu₁ EC₅₀ = 31.8 nM) and highly CNS penetrant (brain to plasma ratio (*K_p*) of 1.02) mGlu₁ PAM tool compound, that potentiated not only wild-type human mGlu₁ but also mutant mGlu₁ receptors derived from deleterious *GRM1* mutations found in schizophrenic patients. Moreover, both electrophysiological and in vivo studies indicate the mGlu₁ ago-PAMs/PAMs do not possess the same epileptiform adverse effect liability as mGlu₅ ago-PAMs/PAMs and maintain temporal activity suggesting a broader therapeutic window.

*Corresponding Author: craig.lindsley@vanderbilt.edu. Phone: 615-322-8700. Fax: 615-343-3088.

Author Contributions

P.M.G.-B. performed chemical synthesis and molecular pharmacology. H.P.C. performed molecular pharmacology and mutagenesis. C.M.N., P.J.C., and C.W.L. oversaw the molecular pharmacology and mutagenesis. F.W.B. did all animal dosing and drawing. C.W.L. and A.L.B. performed and analyzed all DMPK studies. Z.X. performed the electrophysiology, and J.M.R. performed the in vivo behavioral studies. C.W.L. oversaw all aspects of the work (medicinal chemistry, pharmacology, DMPK) and wrote the manuscript.

Notes

The authors declare no competing financial interest.

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmed-chem.5b00727.

Detailed pharmacology, DMPK, electrophysiology, and in vivo behavioral methods (PDF)

Molecular formula strings (CSV)

Graphical Abstract

INTRODUCTION

Since the discovery in the 1980s that glutamate (Glu) activated metabotropic glutamate (mGlu) receptors, in addition to α -amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and *N*-methyl-D-aspartate (NMDA) receptors, these class C GPCRs have been the focus of intense research and drug discovery efforts.^{1,2} There are eight subtypes of mGlu receptors, mGlu_{1–8}, that are classified into three groups (group I, mGlu_{1,5}; group II, mGlu_{2,3}; group III, mGlu_{4,6,7,8}) based on sequence homology, pharmacology, and signal transduction mechanism.¹ While early efforts to understand the physiological role of group I mGlu receptors relied on orthosteric, “glutamate-derived” agonists, excitotoxicity and seizure liability limited their utility.^{1–9} Later efforts employed allosteric ligands that afforded subtype selectivity as well as mitigation of the adverse pharmacology by mimicking physiological conditions.^{1–9} Of the group I mGlus, mGlu₅ is by the far the most understood, due in large part to a diverse array of allosteric ligands, both positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs), for which clinical candidates have been developed (and clinical proof-of-concept has been shown in the case of mGlu₅ NAMs).^{5–12} In contrast, a diverse array of mGlu₁ NAMs exists,² but very few mGlu₁ PAMs have been reported, despite being the first PAMs for any mGlu receptor.³ The first generation mGlu₁ PAMs **1–3** and **5** were developed by Roche (Figure 1) in the early 2000s and were potent (mGlu₁ EC₅₀ values of 56–200 nM), but the drug metabolism and pharmacokinetic (DMPK) profiles were poor and the majority displayed significant species differences (only **2** and **5** proved to potentiate both human and rat mGlu₁).^{13–16} While **5** has been used in the literature to validate the role of mGlu₁ in various CNS disorders,^{17–20} it is highly protein bound (F_u = 0.01), CNS penetration is modest (K_p = 0.29), and it possesses a short half-life ($t_{1/2}$ = 54 min) in rat, rendering **5**, as well as the later introduced **4**, less than ideal as in vivo tool compounds by today’s standards. However, as the only mGlu₁ PAM tool compound with CNS exposure, the field had no other option than to employ the lone existing tool to validate and understand the receptor’s role in numerous CNS disorders.^{17–20} Thus, to provide an mGlu₁ PAM in vivo tool compound with a more desired profile (F_u > 3%, K_p > 0.8, clean CYP profiles) to ensure robust target engagement and validation, as well as a distinct chemotype to avoid chemo-type-related pharmacology, our lab has recently focused on the development of next generation mGlu₁ PAMs and ago-PAMs.

While our interest has historically resided in the development of mGlu₅ PAMs and NAMs for various CNS disorders,^{5–12} two recent, independent studies identified 12 rare, deleterious nonsynonymous single nucleotide polymorphisms (nsSNPS) in the *GRM1* gene, which encodes mGlu₁, in schizophrenic patients.^{21,22} These findings led us to explore these loss of function mutant receptors and assess if signaling could be restored with an mGlu₁ PAM.^{23,24}

In lieu of an HTS campaign to provide the desired mGlu₁ tool compounds, we relied on the propensity of certain allosteric ligands to possess “molecular switches”.^{25,26} In this case, an iterative parallel synthesis optimization effort focused on the mGlu₄ PAM **6** (based on an *N*-(3-chloro-4-((3*aR*,4*S*,7*R*,7*aS*)-1,3-dioxo-1,3,3*a*,4,7,7*a*-hexahydro-2*H*-4,7-methanoisindol-2-yl)phenyl)picolinamide scaffold) provided the highly selective mGlu₁ NAM **7** (Figure 2), which underwent a “double molecular switch” (e.g., a switch for mGlu receptor selectivity from mGlu₄ to mGlu₁ as well as a concomitant switch in the mode of pharmacology from PAM to NAM). Further optimization resulted in an additional mode of pharmacology (MoP) “molecular switch” to afford the highly selective mGlu₁ PAM **8** (mGlu₁ EC₅₀ = 390 nM) and a fundamentally new mGlu₁ PAM chemotype.²³ Both Roche’s **5** and our **8** were able to potentiate (i.e., render glutamate a more potent agonist) all of the mutant mGlu₁ receptors (as well human WT mGlu₁) and to restore efficacy (Glu Max) in a limited number of the mutant receptors. There are also double and triple mutants that correlate with even worse disease prognosis, and those are currently being generated for evaluation with mGlu₁ PAMs.^{17,18} Across all of our diverse family A, B, and C GPCR PAM programs, the pharmacological parameters that predict in vivo efficacy vary greatly.^{5–8,27,28} In some case, we observe no effect on *E*_{max}, yet see robust in vivo efficacy, even with a low fold-shift, while for other GPCRs, increases in either *E*_{max} or large fold-shifts are required.^{5–8,27–37} Thus, the ideal pharmacological profile for an mGlu₁ PAM against these mutant receptors is not clear, and we have yet to characterize PAMs against the double and triple mGlu₁ mutants.^{21,22} On the basis of the susceptibility of mGlu₁ to change its response to allosteric modulators due to small changes in its sequence (i.e., the species disconnect observed between human and rat form of the receptor due to a L757V change), we were pleased to see that the mutant mGlu₁ receptors explored could still be modulated with small molecule PAMs.²⁴ Thus, these preliminary data fueled our interest in mGlu₁ as a potential new schizophrenia target for patients harboring these mutations (as well as to revisit other indications for mGlu₁ PAMs); however, the DMPK profile of **8**, while improved over **5** in terms of *K*_p (0.84 vs 0.29),²³ could still be further optimized in order to obtain a more suitable tool for in vivo studies (e.g., improve potency, PK, *F*₀). This is also essential for target validation with a PAM.^{5–8,27,28} Our studies have shown that for some mGlu receptors, such as mGlu₄, free brain levels of the PAM correlate with efficacy, while for others, such as mGlu₅, total brain levels of the PAM afford the most robust correlate.^{5–8,27–37} Thus, to truly validate mGlu₁ PAMs/ago-PAMs across a broad range of CNS disorders, a toolkit of chemical probes with diverse structures, pharmacology, and DMPK profiles are required.

RESULTS AND DISCUSSION

Chemistry

Focused optimization around **8** to enhance mGlu₁ PAM potency and improve the DMPK profile was plagued by crossover activity at mGlu₄, driven in large part by the picolinamide moiety engendering mGlu₄ PAM activity when subtle electronic and/or steric perturbations were performed.^{23,37,38} On the basis of the structure–activity relationships (SAR) we have previously developed around this chemotype for mGlu₄ PAM activity, our optimization plan for **8** was modified to focus on a diverse array of five-membered heterocyclic amides to replace the picolinamide moiety, as well as key substituents on the phthalimide group,

providing analogs **9** (Figure 3).^{23,37,38} Both structural modifications were designed to diminish activity at mGlu₄, but the impact on mGlu₁ PAM activity, while hopeful, was less certain.

As shown in Scheme 1, analogs **9** were readily prepared in three steps from commercial materials and in good overall yields.³⁹ Starting from aniline **11**, condensation with phthalic anhydride in refluxing acetic acid provided **12** in 88% yield. Reduction of the nitro moiety with tin(II) chloride afforded **13** in 72% yield, and a HATU-mediated amide coupling gives analogs **9** in yields ranging from 43% to 96%, depending on the heterocyclic carboxylic acid employed. The same sequence of steps provides the furylamide based analogs **10**. Finally, analogs **17** were also prepared in three steps from aniline **14**. Here, microwave-assisted acylation of **14** with 3-methyl-2-furanyl chloride affords furylamide **15** in 97% yield. Once again, a tin(II) chloride mediated reduction of the nitro group provided aniline **16** (96%), which was condensed with phthalic anhydride in refluxing acetic acid to yield analogs **17** (34–92%).³⁹

SAR for the initial diversity library of analogs **9** was strikingly “flat” (Table 1), with only 2 of 14 analogs possessing any measurable mGlu₁ PAM activity. The 2-furylamide congener **9a** was the most active (mGlu₁ EC₅₀ = 550 nM, pEC₅₀ = 6.26 ± 0.10, 76 ± 6% Glu Max), while related derivatives, such as the 2-thienyl **9b** and 2-pyrrolyl **9c** were devoid of mGlu₁ activity (mGlu₁ EC₅₀ values of >10 μM). Only the 4-thiazolyl analog **9h** showed modest activity (mGlu₁ EC₅₀ = 4.5 μM, pEC₅₀ = 5.35 ± 0.10, 107 ± 7% Glu Max), while the regioisomeric thiazole **9i** was inactive, as were oxazoles (**9d** and **9e**), other aza-congeners, as well as a tetrahydrofuran **9n**. It is worth noting that the inactive compounds described did not decrease the glutamate response during the screening, which excludes a switch of mode of pharmacology to NAMs as it has been observed in other cases; however, the possibility that these modifications could generate silent allosteric modulator (SAMs) or a “molecular switch” that changes the subtype selectivity toward other mGlu receptor has not been explored or ruled out.

On the basis of these data, we prepared a library of diverse furylamides **10**, surveying a wide range of substituents (Table 2). Like analogs **9**, SAR for this series was similarly “flat”; however, many of these analogs showed weak PAM activity at ~10 μM (% Glu Max 30–60%). Again, a single derivative **10j**, a 3-methylfuryl congener, emerged with promising activity (mGlu₁ EC₅₀ = 97 nM, pEC₅₀ = 7.01 ± 0.15, 118 ± 3% Glu Max). Interestingly, substituents in the 5-position (**10a–i**) were uniformly inactive, as were fused benzofurans **10m** and **10n**. Addition of a methyl group to the 5-position of **10j**, providing the 3,5-dimethyl analog **10l**, also resulted in a loss of mGlu₁ PAM activity.

The next round of optimization held the 3-methylfurylamide of **10j** constant and surveyed alternative substituents on the phthalimide moiety delivering analogs **17** (Table 3), providing, for the first time, robust SAR and a collection of potent and highly efficacious mGlu₁ PAMs (EC₅₀ values of 24.3–98.8 nM). In this instance, small groups in either the 3- or 4-position of the phthalimide moiety afforded potent mGlu₁ PAMs (**17a–f**), and the 4-aza derivative was also tolerated (**17g**). Efficacy (% Glu Max) was tightly maintained (86–98%)

across all analogs **17**. Surprisingly, analogs **17** all retained some residual mGlu₄ PAM activity, with selectivity versus mGlu₄ ranging from 5.9- to >100-fold.

Molecular Pharmacology

From this set of analogs **17** (Table 3), three compounds were selected for further characterization: **17d**, the 4-Cl analog (mGlu₁ EC₅₀ = 80.9 nM, pEC₅₀ = 7.09 ± 0.10, 94 ± 9% Glu Max, 27.7-fold versus mGlu₄); **17e**, the 3-F analog (mGlu₁ EC₅₀ = 31.8 nM, pEC₅₀ = 7.49 ± 0.15, 98 ± 6% Glu Max, 34.9-fold versus mGlu₄); and **17g** the 4-aza analog (mGlu₁ EC₅₀ = 98.8 nM, pEC₅₀ = 7.01 ± 0.08, 94 ± 4% Glu Max, >100-fold versus mGlu₄).³⁹ These three analogs displayed comparable potency at rat mGlu₁ and enhanced efficacy and represent a 3- to >10-fold improvement in mGlu₁ PAM potency over our initial lead mGlu₁ PAM **8** (Figure 4). As shown in Figure 5, all three mGlu₁ PAMs induced a parallel leftward shift of the glutamate concentration–response curve (CRC). **17d** induces a maximum 8.3-fold shift at 10 μM, with modest agonism (<20%) noted at the highest concentration. **17e** induces a maximum 11.4-fold shift at 10 μM, with higher levels of agonism (~35%) noted at the highest concentration, and **17f** induces a maximum 10.9-fold shift at 10 μM, with modest agonism (<20%) noted at the highest concentration in cells expressing human mGlu₁. On the basis of these profiles, these modulators are best described as mGlu₁ ago-PAMs in this calcium mobilization assay, though the degree of allosteric agonism varies.^{23,24,39} As glutamatergic tone may vary across brain regions, possessing tool compounds with a range of pure PAM to ago-PAM activity is very attractive and will be useful in in vivo proof of concept studies and translation.^{5–8,27,28} We also assessed selectivity of **17d**, **17e**, and **17g** versus the other remaining six mGlu receptors in our standard fold-shift assay paradigm at a 10 μM concentration.^{30,31,33,36} **17d** and **17g** were selective against mGlu_{2,3,5,6,7,8}, inducing less than a ~2-fold shift of the glutamate CRC at 10 μM. **17e** was selective versus mGlu_{2,3,8} (less than ~2-fold shift of glutamate CRC at 10 μM, a modest 2.7-fold shift at mGlu₅, and larger shifts at mGlu₆ (6.7) and mGlu₇ (7.0). Thus, the mGlu₁ PAMs are suitable for in vivo studies.

Metabolism and Disposition

A major goal of the optimization effort was to improve not only mGlu₁ PAM potency but also the DMPK profile relative to the lead **8** (and **5**) to provide an in vivo tool compound. A hallmark of the earlier mGlu₁ PAMs was moderate to high clearance in rodent species, mixed cytochrome P450 (CYP) profiles, poor CNS penetration (in the case of **5**, $K_p < 0.3$), and in the case of **8**, instability in human and rat plasma, making it impossible to assess free fraction (F_u) and thus free drug levels.²³ Therefore, we profiled **5**, **8**, **17d**, **17e**, and **17g** in a battery of in vitro and in vivo DMPK assays (Table 4) to determine if this second generation series of mGlu₁ PAMs addressed key issues.³⁹ As shown in Table 4, all three analogs addressed different aspects of the major limitations (low K_p , high plasma protein binding and plasma instability). **17d** displayed low hepatic clearance in both human (CL_{HEP} = 2.54 mL min^{−1} kg^{−1}) and rat (CL_{HEP} = 17.2 mL min^{−1} kg^{−1}), a clean CYP profile (IC₅₀ > 30 μM versus CYP 1A2, 2C9, 2D6, and 3A4), moderate in vivo clearance (CL_p = 33 mL min^{−1} kg^{−1}), reasonable half-life ($t_{1/2}$ = 91 min), and good CNS penetration (brain/plasma ratio K_p of 0.63). However, **17d**, like **8**, was unstable in both human and rat plasma, though

acceptable in vivo. In contrast, **17g**, the 4-aza congener, displayed high hepatic clearance in both human ($CL_{HEP} = 18.6 \text{ mL min}^{-1} \text{ kg}^{-1}$) and rat ($CL_{HEP} = 59.7 \text{ mL min}^{-1} \text{ kg}^{-1}$), a clean CYP profile ($IC_{50} > 30 \text{ }\mu\text{M}$ versus CYP 1A2, 2C9, 2D6, and 3A4), superhepatic in vivo clearance ($CL_p = 283 \text{ mL min}^{-1} \text{ kg}^{-1}$), exceedingly short half-life ($t_{1/2} = 5.4 \text{ min}$), yet high CNS penetration (brain/plasma ratio K_p of 2.81). Interestingly, **17g** was unstable in human plasma but stable in rat plasma ($f_u = 0.03$). **17e** represents a middle ground between these two extremes of disposition and emerged as the mGlu₁ ago-PAM with the most balanced profile for in vivo studies. For the first time in this series, **17e** was stable in both human and rat plasma, enabling determination of plasma free fraction (human $f_u = 0.05$, rat $f_u = 0.03$). **17e** displayed low hepatic clearance in human ($CL_{HEP} = 2.70 \text{ mL min}^{-1} \text{ kg}^{-1}$) and high in rat ($CL_{HEP} = 59.7 \text{ mL min}^{-1} \text{ kg}^{-1}$) and a mixed but acceptable CYP profile ($IC_{50} > 30 \text{ }\mu\text{M}$ versus CYP 2D6 and 3A4, $IC_{50} = 25.2 \text{ }\mu\text{M}$ at 1A2, $IC_{50} = 6.45 \text{ }\mu\text{M}$ at 2C9). Interestingly, there was not a good in vitro/in vivo (IVIVC) correlation, as **17e** possessed low in vivo clearance ($CL_p = 13.3 \text{ mL min}^{-1} \text{ kg}^{-1}$), a comparable half-life ($t_{1/2} = 53.6 \text{ min}$) to **5**, and improved CNS penetration (brain/plasma ratio K_p of 1.02).

The plasma instability of **8**, **17d**, and **17g** was not entirely unexpected based on literature precedent with reported hydrolysis of phthalimide-containing drugs in plasma.^{40,41} To assess this as the source of plasma instability, we evaluated **17d** in rat and human plasma at a $10 \text{ }\mu\text{M}$ incubation concentration at 0 and 4 h time points at $37 \text{ }^{\circ}\text{C}$ (Figure 6) and analyzed it by mass spectrometry to identify metabolites.³⁹ In both rat and human plasma, the parent compound is clearly present at $t = 0$, but by 4 h, no parent **17d** remains, but three metabolites are formed: M1 (major), M2 (major), and M3 (minor). As predicted from the literature, M1 and M2 correspond to hydrolysis of the phthalimide to afford the two regioisomeric phthalamic acids, M1 and M2, and the aniline M3, resulting from amide hydrolysis of M1 and M2. However, the presence of the electronegative fluorine atom in **17e**, presumably from inductive effects, stabilizes the phthalimide moiety to enable stability in plasma such that F_u can be determined.

Activity at GRM1 Mutants

Though selective mGlu₁ activation has been suggested as a mechanism for therapeutic intervention in a variety of CNS disorders, our interest primarily resides in schizophrenia and the presence of mutant mGlu₁ receptors derived from deleterious *GRM1* mutations found in schizophrenic patients (Figure 7).^{21,22} Recently we reported that we developed stable HEK-293 cell lines expressing 9 of the 12 mGlu₁ mutant receptors, confirmed that they were loss-of-function mutations and not due to loss of receptor cell surface expression and that mGlu₁ PAMs **5** and **8** could potentiate calcium signaling induced by activation of these mutant receptors with glutamate or *S*-3,5-dihydroxyphenylglycine (DHPG), restoring functionality in cells expressing mGlu₁ possessing K563N and P1015A mutations (i.e., those which had only a small negative impact on glutamate signaling), while in other mutants, enhancements in glutamate potency, but not efficacy, were observed.²³ Thus, mGlu₁ PAMs may be a viable therapeutic intervention in patients harboring these mutations. We selected four of the nine single point mutant receptors (Figure 7), three in the transmembrane domain (P729T, A863E, Y632H) and one in the intracellular C-terminal domain (P1014S), and evaluated the ability of the three PAMs to restore the reduction in

glutamate-mediated calcium signaling utilizing a fold-shift experiment as shown previously for human WT mGlu₁ (Figure 5). It was pleasing to see that the SAR driven on human mGlu₁ to deliver the second generation mGlu₁ PAMs is retained across WT and the mutant mGlu₁ receptors. Across the four mutants, mGlu₁ PAMs **17d**, **17e**, and **17g** induce a parallel-leftward shift of the glutamate CRC, providing maximum shifts of ~10-fold at 10 μ M compound concentration and, in some cases, modest increases in glutamate efficacy (Figure 8). Similar to human WT mGlu₁, **17e** displayed robust ago-PAM activity across all four mutants (up to ~40%), and this was noted at concentrations of compound above 1 μ M, while ago-PAM activity was greatly diminished for **17d** and **17g** at these mutants compared to the WT receptor. As the major deficit in these mutant receptors is the decrease in the efficacy of the receptor signal, the possibility of these probes having a therapeutic benefit in schizophrenic patients carrying these mutations is still an open question. The increase in sensitivity toward glutamate might be beneficial; however, in vivo studies in mutant mice harboring these mutations should be carried out in order to assess if this feature is sufficient to observe an improvement in the phenotype.

Adverse Effect Liability

While early efforts to understand the physiological role of group I mGlu receptors relied on orthosteric, “glutamate-derived” agonists, excitotoxicity, and seizure liability limited their utility.^{1–9} For example, the group I dual mGlu_{1/5} agonist DHPG induces severe epileptiform activity,^{42,43} and this liability weighed heavily on early mGlu₅ PAM programs,^{30,31,42–47} as it was not clear if this was due to mGlu₁, mGlu₅, or both; moreover, it was not clear if a pure mGlu₅ PAM would avoid this liability.^{42–47} Since this field has matured, multiple mGlu₅ PAMs, across diverse chemotypes that possessed even modest ago-PAM or pure PAMs that in vivo generated ago-PAM metabolites activity, have been shown to induce epileptiform activity in rat hippocampal CA3 region in vitro as well as racine scale (4+) seizures in rodents.^{30,31,42–47} This severe adverse effect liability has hindered and slowed the development of this promising antipsychotic target. Thus, with the development of **17e**, we were poised to assess the adverse effect liability of an mGlu₁ ago-PAM/PAM with excellent CNS penetration and free drug levels. To determine if a selective mGlu₁ ago-PAM/PAM has any effect in inducing the epileptiform activity, we performed experiments analogous to those described in the previous studies and recorded spontaneous extracellular spike activity from CA3 pyramidal cell body layer in a mouse hippocampal slice preparation.^{34,43} Bath application of the mGlu₁ PAM **17e** (10 μ M, >300-fold above the mGlu₁ EC₅₀) did not induce epileptiform activity, reflected by no change in frequency of spontaneous spike activity following application of the mGlu₁ PAM (Figure 9). The frequency of spike activity after application of 10 μ M **17e** was 1.16 ± 0.44 Hz, which is not significantly different from the baseline control (0.99 ± 0.38 Hz; $p = 0.38$, $n = 6$, paired t test), despite possessing ~35% agonism of mGlu₁ at this concentration. As a positive control, we applied the group I mGlu agonist DHPG, which induced marked epileptiform activity, as evidenced by a robust increase in frequency of spontaneous activity following application of 50 μ M DHPG (13.8 ± 3.0 Hz, compared to 0.94 ± 0.06 Hz in baseline control; $p = 0.0084$, $n = 6$, paired t test).³⁹

Previous reports have demonstrated that intracerebroventricular injections of the group I mGlu agonist DHPG can induce behavioral convulsions in rats.^{39,42,43} DHPG activates both

mGlu₁ and mGlu₅ receptors. Our group has previously shown that mGlu₅ ago-PAM (*R*)-5-((3-fluorophenyl)ethynyl)-*N*-(3-hydroxy-3-methylbutan-2-yl)picolinamide (VU0424465, **18**) causes seizure activity and behavioral convulsions in rats.⁴⁴ Therefore, to assess the potential contributions of mGlu₁ activation in the induction of seizure activity, we evaluated the behavioral effects of selective mGlu₁ PAMs, **17d**, **17e**, and **17g** alongside the selective mGlu₅ ago-PAM **18** in mice.³⁹ Male C57Bl/6 mice (25–30g) were administered mGlu₅ ago-PAM **18** (1 or 3 mg/kg ip) or mGlu₁ ago-PAMs **17d**, **17e**, or **17g** (100 mg/kg ip), and behavioral responses were monitored continuously for 3 h. Behavioral convulsions were measured using a modified Racine score (0–5). Systemic administration of **18** induced severe, dose-dependent behavioral manifestations of seizure activity with peak responses observed approximately 5 min after administration (Figure 10) in accord with previous data in rats.⁴⁴ In contrast, administration of a much higher dose of the mGlu₁ ago-PAM **17d**, **17e**, or **17g** induced no measurable behavioral disturbances at any time point (Figure 10).³⁹ Of note, **17e** achieved total brain exposure of 9.2 μ M, ~288-fold above the mGlu₁ PAM EC₅₀ (31.8 nM) and >10-fold when corrected for free drug levels (rBHB F_u = 0.04). Similarly, **17d** and **17g** achieved total brain levels of 1.4 and 2.52 μ M, respectively, both an order of magnitude above their respective mGlu₁ EC₅₀ values. Therefore, selective mGlu₁ activation did not induce observable seizure activity or behavioral convulsions despite achieving high brain concentrations that are significantly higher than those required for maximum potentiation of mGlu₁ activation, and these in vivo data are supported by the electrophysiology data (Figure 9). To ensure this was not a chemotype driven effect, we also assessed Roche's **5** in this model at 100 mg/kg ip. For the first time, these data suggest that the epileptiform activity induced by the group I dual mGlu_{1/5} agonist is solely mediated by agonism at mGlu₅, and both in vitro electrophysiology data and in vivo data support this conclusion; moreover, these findings suggest that mGlu₁ ago-PAMs/PAMs may have a larger therapeutic window than mGlu₅ ago-PAMs/PAMs and avoid this key adverse effect liability.

CONCLUSION

In summary, we optimized a series of mGlu₁ PAMs based on an *N*-(3-chloro-4-(1,3-dioxoisindolin-2-yl)phenyl)-3-methylfur-an-2-carboxamide scaffold, driven by multidimensional, iterative parallel synthesis to provide a second generation of potent and CNS penetrant mGlu₁ PAMs (**17d**, **17e**, and **17g**) with DMPK profiles to enable in vivo proof of concept studies. All three PAMs potentiated not only wild-type human mGlu₁ but also mutant mGlu₁ receptors derived from deleterious *GRM1* mutations found in schizophrenic patients, which will enable translational studies. From this effort, **17e**, a potent (mGlu₁ EC₅₀ = 31.8 nM) and highly CNS penetrant (brain to plasma ratio (K_p) of 1.02) mGlu₁ PAM emerged as a new in vivo proof-of-concept tool compound, along with **17d** and **17g**, with a balanced DMPK profile and overcoming key liabilities of its predecessors **5** and **8**. Moreover, we showed for the first time that mGlu₁ ago-PAMs do not induce epileptiform activity in the CA3 region of the hippocampus and do not induce seizures in vivo at drug concentrations far above the mGlu₁ PAM EC₅₀, suggesting that the adverse effect liability of group I agonists, such as DHPG, is solely mediated by agonism at mGlu₅. Further in vivo studies and continuing efforts around this scaffold are in progress and will be reported in due course.

EXPERIMENTAL SECTION

Chemistry

All reactions were carried out employing standard chemical techniques under inert atmosphere. Solvents used for extraction, washing, and chromatography were HPLC grade. Unless otherwise noted, all reagents were purchased from Aldrich Chemical Co. and were used without further purification. Analytical thin layer chromatography was performed on 250 μ m silica gel plates from Sorbent Technologies. Analytical HPLC was performed on an Agilent 1200 LCMS with UV detection at 215 and 254 nm along with ELSD detection and electrospray ionization, with all final compounds showing >95% purity and a parent mass ion consistent with the desired structure. All NMR spectra were recorded on a 400 MHz Brüker AV-400 instrument. ^1H chemical shifts are reported as δ values in ppm relative to the residual solvent peak (DMSO- d_6 = 2.50, CDCl_3 = 7.26). Data are reported as follows: chemical shift, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = multiplet), coupling constant (Hz), and integration. ^{13}C chemical shifts are reported as δ values in ppm relative to the residual solvent peak (DMSO- d_6 = 39.52, CDCl_3 = 77.16). Low resolution mass spectra were obtained on an Agilent 1200 LCMS with electrospray ionization. High resolution mass spectra were recorded on a Waters QToF-API-US plus Acquity system with electrospray ionization. Automated flash column chromatography was performed on a Teledyne ISCO Combiflash Rf system. Preparative purification of library compounds was performed on a Gilson 215 preparative LC system. Purity for all final compounds was >95%, and each showed a parent mass ion consistent with the desired structure (LCMS).

2-(2-Chloro-4-nitrophenyl)isoindoline-1,3-dione (12)—In a flask, 200 mg (1.622 mmol, 1.2 equiv) of 2-chloro-4-nitroaniline and 280 mg (1.350 mmol, 1.0 equiv) of phthalic anhydride were added and dissolved in 5 mL of acetic acid. The mixture was refluxed for 24 h. After cooling the solution a precipitate is formed. The solid was filtered and carefully triturated with cold methanol to obtain a light yellow powder (359 mg, 88%). ^1H NMR (400.1 MHz, CDCl_3) δ (ppm): 8.45 (1H, d, J = 2.4 Hz), 8.28 (1H, dd, J = 8.7 Hz, J = 2.5 Hz), 8.00 (2H, m), 7.86 (2H, m), 7.58 (1H, d, J = 8.6 Hz). ^{13}C NMR (100.6 MHz, CDCl_3) δ (ppm): 165.6, 148.2, 135.6, 134.9, 134.6, 131.6, 131.4, 125.7, 124.2, 122.6.

2-(4-Amino-2-chlorophenyl)isoindoline-1,3-dione (13)—In a vial, 300 mg (0.993 mmol, 1.0 equiv) of **12** were resuspended in dioxane. The suspension was cold in an ice bath and purged with argon. A previously prepared solution of tin(II) chloride (847 mg, 4.469 mmol, 4.5 equiv) in concentrated hydrochloric acid (5 M concentration of SnCl_2) was added dropwise to the suspension. After 2 h of stirring at room temperature, the reaction was neutralized carefully with aqueous potassium carbonate 20%, filtered, and extracted with diethyl ether. The organic phase was dried with magnesium sulfate, filtered and the volatiles were eliminated in vacuo to yield a yellow powder (196 mg, 72%). ^1H NMR (400.1 MHz, DMSO- d_6) δ (ppm): 7.97 (2H, m), 7.90 (2H, m), 7.14 (1H, d, J = 8.5 Hz), 6.76 (1H, d, J = 2.4 Hz), 6.60 (1H, dd, J = 8.6 Hz, J = 2.4 Hz), 5.74 (2H, s, $-\text{NH}_2$). ^{13}C NMR (100.6 MHz, DMSO- d_6) δ (ppm): 167.5, 151.5, 135.3, 132.7, 131.78, 131.76, 123.9, 116.5, 113.6, 113.0.

General Synthesis of *N*-(3-Chloro-4-(1,3-dioxoisindolin-2-yl)phenyl)amides (9 and 10)—In a vial, 0.088 mmol (1.2 equiv) of the carboxylic acid was added and dissolved in 0.5 mL mixture of DCM/DIEA (9:1), then an amount of 41 mg (0.110 mmol, 1.5 equiv) of HATU was added. The mixture was stirred for 10 min, and an amount of 20 mg (0.073 mmol, 1.0 equiv) of **13** dissolved in 0.5 mL of DCM/DIEA (9:1) was added, followed by 3 drops of DMF. The reaction was stirred for 24 h at room temperature. After this time, the reaction was quenched with the addition of water and was worked up by extraction with DCM (2 mL, thrice). The organic phase was filtered through a phase separator, volatiles were evaporated, the crude was dissolved in DMSO and purified by preparative HPLC.

***N*-(3-Chloro-4-(1,3-dioxoisindolin-2-yl)phenyl)-3-methyl-furan-2-carboxamide (10j)**—Cream powder. ^1H NMR (400.1 MHz, CDCl_3) δ (ppm): 8.14 (1H, s), 8.06 (1H, d, $J = 2.4$ Hz), 7.97 (2H, m), 7.81 (2H, m), 7.64 (1H, dd, $J = 8.6$ Hz, $J = 2.4$ Hz), 7.40 (1H, d, $J = 1.5$ Hz), 7.32 (1H, d, $J = 8.6$ Hz), 6.43 (1H, d, $J = 1.5$ Hz), 2.47 (3H, s). ^{13}C NMR (100.6 MHz, CDCl_3) δ (ppm): 166.7, 157.1, 142.8, 141.4, 139.6, 134.4, 133.7, 131.8, 130.8, 129.9, 124.8, 123.9, 120.8, 118.3, 116.0, 11.2. HRMS (TOF, ES+) $\text{C}_{20}\text{H}_{14}\text{ClN}_2\text{O}_4$ $[\text{M} + \text{H}]^+$ calcd mass 381.0642, found 381.0644.

***N*-(2-Chloro-4-nitrophenyl)-3-methylfuran-2-carboxamide (15)**—In a microwave vial, an amount of 912 mg (5.28 mmol, 1.2 equiv) of 2-chloro-4-nitroaniline was added and dissolved in 20 mL of DCE/DIEA (9:1), followed by addition of 500 μL (4.40 mmol, 1.0 equiv) of the 3-methylfurancarboxyl chloride. The reaction was heated in the microwave at 120 $^\circ\text{C}$ for 30 min. The reaction was cooled to room temperature and water was added, causing the precipitation of the product. The crude was filtrated in vacuo and titrated with methanol to give a cream solid (1195 mg, 97% yield). ^1H NMR (400.1 MHz, $\text{DMSO}-d_6$) δ (ppm): 10.71 (1H, s), 8.27 (1H, d, $J = 2.2$ Hz), 8.14 (1H, d, $J = 9.1$ Hz), 7.99 (1H, dd, $J = 9.1$ Hz, $J = 2.2$ Hz), 7.88 (1H, d, $J = 1.5$ Hz), 6.66 (1H, d, $J = 1.5$ Hz), 2.37 (3H, s). ^{13}C NMR (100.6 MHz, $\text{DMSO}-d_6$) δ (ppm): 158.1, 144.9, 144.3, 141.9, 141.4, 130.3, 127.7, 126.9, 121.7, 119.0, 116.4, 11.5. HRMS (TOF, ES+) $\text{C}_{12}\text{H}_9\text{ClN}_2\text{O}_4$ $[\text{M}^+]$ calcd mass 280.0251, found 280.0254.

***N*-(4-Amino-2-chlorophenyl)-3-methylfuran-2-carboxamide (16)**—In a flask, an amount of 480 mg (1.71 mmol, 1.0 equiv) of **15** was suspended in dioxane. The suspension was cold in an ice bath and purged with argon. A previously prepared solution of tin(II) chloride (1.45 g, 7.70 mmol, 4.5 equiv) in concentrated hydrochloric acid (5 M concentration of SnCl_2) was added dropwise to the suspension. After 2 h of stirring at room temperature, the reaction was neutralized carefully with aqueous potassium carbonate 20%, filtered, and extracted with diethyl ether. The organic phase was dried with magnesium sulfate, filtered and the volatiles were eliminated in vacuo to yield a cream solid (410 mg, 96% yield). ^1H NMR (400.1 MHz, $\text{DMSO}-d_6$) δ (ppm): 9.87 (1H, s), 7.76 (1H, d, $J = 1.6$ Hz), 7.74 (1H, d, $J = 2.3$ Hz), 7.41 (1H, dd, $J = 8.7$ Hz, $J = 2.3$ Hz), 6.82 (1H, d, $J = 8.7$ Hz), 6.58 (1H, d, $J = 1.6$ Hz), 5.51 (2H, br), 2.32 (3H, s). ^{13}C NMR (100.6 MHz, $\text{DMSO}-d_6$) δ (ppm): 157.5, 143.8, 142.3, 139.8, 129.9, 127.7, 121.8, 121.2, 117.8, 116.4, 116.0, 11.4. HRMS (TOF, ES +) $\text{C}_{12}\text{H}_{11}\text{ClN}_2\text{O}_2$ $[\text{M}^+]$ calcd mass 250.0509, found 250.0513.

General Synthesis of Substituted *N*-Acyl-*N*-(4-aminophenyl)-3-methylfuran-2-carboxamides (17)—In a vial, 30 mg (0.12 mmol, 1.0 equiv) of the aniline and 0.18 mmol (1.5 equiv) of the phthalic anhydride were added and dissolved in 1 mL of acetic acid. The mixture was heated at 110 °C while stirring for 4 h. After this time, volatiles were evaporated, the crude was dissolved in DMSO and resolved by preparative HPLC.

***N*-(3-Chloro-4-(4-methyl-1,3-dioxoisindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide (17a)**—Cream powder. ¹H NMR (400.1 MHz, CDCl₃) δ(ppm): 8.15 (1H, s), 8.05 (1H, d, *J* = 2.4 Hz), 7.79 (1H, d, *J* = 7.4 Hz), 7.65 (2H, m), 7.55 (1H, d, *J* = 7.7 Hz), 7.39 (1H, d, *J* = 1.5 Hz), 7.29 (1H, d, *J* = 8.6 Hz), 6.43 (1H, d, *J* = 1.6 Hz), 2.47 (3H, s), 2.46 (3H, s). ¹³C NMR (100.6 MHz, CDCl₃) δ(ppm): 167.5, 166.8, 157.1, 142.8, 141.4, 139.5, 138.6, 136.7, 133.9, 133.8, 132.3, 130.8, 129.9, 128.6, 125.0, 121.5, 120.8, 118.2, 116.0, 17.7, 11.2. HRMS (TOF, ES+) C₂₁H₁₆ClN₂O₄ [M + H]⁺ calcd mass 395.0799, found 395.0798.

***N*-(3-Chloro-4-(5-methyl-1,3-dioxoisindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide (17b)**—Cream powder. ¹H NMR (400.1 MHz, CDCl₃) δ(ppm): 8.15 (1H, s), 8.05 (1H, d, *J* = 2.3 Hz), 7.84 (1H, d, *J* = 7.7 Hz), 7.77 (1H, d, *J* = 7.4 Hz), 7.62 (1H, dd, *J* = 8.6 Hz, *J* = 2.4 Hz), 7.59 (1H, d, *J* = 7.7 Hz), 7.38 (1H, d, *J* = 1.5 Hz), 7.30 (1H, d, *J* = 8.6 Hz), 6.42 (1H, d, *J* = 1.5 Hz), 2.56 (3H, s), 2.46 (3H, s). ¹³C NMR (100.6 MHz, CDCl₃) δ(ppm): 166.9, 166.8, 157.1, 145.8, 142.8, 141.4, 139.6, 135.0, 133.8, 132.2, 130.8, 129.9, 129.2, 124.9, 124.4, 123.8, 120.8, 118.3, 116.0, 22.0, 11.2. HRMS (TOF, ES+) C₂₁H₁₆ClN₂O₄ [M + H]⁺ calcd mass 395.0799, found 395.0798.

***N*-(3-Chloro-4-(4-chloro-1,3-dioxoisindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide (17c)**—Cream powder ¹H NMR (400.1 MHz, CDCl₃) δ(ppm): 8.16 (1H, s), 8.06 (1H, d, *J* = 2.3 Hz), 7.88 (1H, m), 7.74 (2H, m), 7.63 (1H, dd, *J* = 8.6 Hz, *J* = 2.3 Hz), 7.39 (1H, d, *J* = 1.2 Hz), 7.29 (1H, d, *J* = 8.6 Hz), 6.42 (1H, d, *J* = 1.2 Hz), 2.46 (3H, s). ¹³C NMR (100.6 MHz, CDCl₃) δ(ppm): 165.2, 164.3, 157.2, 142.9, 141.4, 139.8, 136.1, 135.2, 133.9, 133.7, 132.0, 130.7, 130.0, 127.6, 124.4, 122.3, 120.8, 118.3, 116.1, 11.2. HRMS (TOF, ES+) C₂₀H₁₃Cl₂N₂O₄ [M + H]⁺ calcd mass 415.0252, found 415.0254.

***N*-(3-Chloro-4-(5-chloro-1,3-dioxoisindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide (17d)**—Cream powder. ¹H NMR (400.1 MHz, CDCl₃) δ(ppm): 8.16 (1H, s), 8.06 (1H, d, *J* = 2.3 Hz), 7.94 (1H, d, *J* = 1.7 Hz), 7.90 (1H, d, *J* = 8.0 Hz), 7.77 (1H, dd, *J* = 8.0 Hz, *J* = 1.7 Hz), 7.63 (1H, dd, *J* = 8.6 Hz, *J* = 2.3 Hz), 7.40 (1H, d, *J* = 1.4 Hz), 7.30 (1H, d, *J* = 8.6 Hz), 6.43 (1H, d, *J* = 1.4 Hz), 2.46 (3H, s). ¹³C NMR (100.6 MHz, CDCl₃) δ(ppm): 165.8, 165.4, 157.1, 142.9, 141.4, 141.2, 139.8, 134.5, 133.6, 133.5, 130.7, 130.0, 129.8, 125.1, 124.4, 124.3, 120.8, 118.3, 116.1, 11.2. HRMS (TOF, ES+) C₂₀H₁₃Cl₂N₂O₄ [M + H]⁺ calcd mass 415.0252, found 415.0251.

***N*-(3-Chloro-4-(4-fluoro-1,3-dioxoisindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide (17e)**—Cream powder. ¹H NMR (400.1 MHz, CDCl₃) δ(ppm): 8.16 (1H, s), 8.06 (1H, d, *J* = 2.3 Hz), 7.80 (2H, m), 7.65 (1H, dd, *J* = 8.6 Hz, *J* = 2.4 Hz), 7.49 (1H, m), 7.39 (1H, d, *J* = 1.4 Hz), 7.30 (1H, d, *J* = 8.6 Hz), 6.42 (1H, d, *J* = 1.4 Hz), 2.46 (3H, s). ¹³C NMR (100.6 MHz, CDCl₃) δ(ppm): 165.5, 163.3, 157.9 (¹*J*_{CF}, d, *J* = 266 Hz), 157.2,

142.9, 142.7, 141.4, 139.8, 137.0 ($^3J_{\text{CF}}$, d, $J = 7.6$ Hz), 133.8 ($^2J_{\text{CF}}$, d, $J = 22.6$ Hz), 130.8, 130.0, 124.3, 122.7 ($^2J_{\text{CF}}$, d, $J = 19.6$ Hz), 120.8, 120.1 ($^4J_{\text{CF}}$, d, $J = 3.2$ Hz), 118.7, 118.3, 116.1, 11.2. HRMS (TOF, ES+) $\text{C}_{20}\text{H}_{13}\text{ClFN}_2\text{O}_4$ $[\text{M} + \text{H}]^+$ calcd mass 399.0548, found 399.0547.

***N*-(3-Chloro-4-(5-fluoro-1,3-dioxoisindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide (17f)**—Cream powder. ^1H NMR (400.1 MHz, CDCl_3) δ (ppm): 8.16 (1H, s), 8.06 (1H, d, $J = 2.3$ Hz), 7.97 (1H, dd, $J = 8.2$ Hz, $J = 4.5$ Hz), 7.64 (2H, m), 7.47 (1H, td, $J = 8.5$ Hz, $J = 2.2$ Hz), 7.40 (1H, d, $J = 1.5$ Hz), 7.30 (1H, d, $J = 8.6$ Hz), 6.43 (1H, d, $J = 1.5$ Hz), 2.47 (3H, s). ^{13}C NMR (100.6 MHz, CDCl_3) δ (ppm): 165.6, 165.3, 157.1, 142.9, 141.4, 139.8, 134.6 ($^3J_{\text{CF}}$, d, $J = 9.7$ Hz), 133.7, 130.7, 130.0, 127.6 ($^4J_{\text{CF}}$, d, $J = 2.9$ Hz), 126.3 ($^3J_{\text{CF}}$, d, $J = 9.1$ Hz), 124.5, 121.5 ($^2J_{\text{CF}}$, d, $J = 22.9$ Hz), 120.8, 118.3, 116.1, 111.6 ($^2J_{\text{CF}}$, d, $J = 25.0$ Hz), 11.2. HRMS (TOF, ES+) $\text{C}_{20}\text{H}_{13}\text{ClFN}_2\text{O}_4$ $[\text{M} + \text{H}]^+$ calcd mass 399.0548, found 399.0546.

***N*-(3-Chloro-4-(1,3-dioxo-1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl)-3-methylfuran-2-carboxamide (17g)**—Cream powder. ^1H NMR (400.1 MHz, $\text{DMSO}-d_6$) δ (ppm): 10.47 (1H, s), 9.31 (1H, s), 9.21 (1H, d, $J = 4.8$ Hz), 8.21 (1H, d, $J = 2.2$ Hz), 8.06 (1H, d, $J = 4.8$ Hz), 7.92 (1H, dd, $J = 8.7$ Hz, $J = 2.2$ Hz), 7.86 (1H, d, $J = 1.4$ Hz), 7.56 (1H, d, $J = 8.7$ Hz), 6.65 (1H, d, $J = 1.4$ Hz), 2.37 (1H, s). ^{13}C NMR (100.6 MHz, $\text{DMSO}-d_6$) δ (ppm): 166.2, 165.9, 158.0, 156.8, 145.1, 144.5, 141.7, 141.4, 139.3, 132.3, 131.5, 129.4, 125.9, 124.1, 121.1, 120.0, 117.8, 116.3, 11.5. HRMS (TOF, ES +) $\text{C}_{19}\text{H}_{12}\text{ClN}_3\text{O}_4$ $[\text{M}]^+$ calcd mass 381.0516, found 381.0519.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was generously supported by the Warren Family and William K. Warren Foundation (who also funded with William K. Warren, Jr., Chair in Medicine to C.W.L.) and Grant NIH/MLPCN U54 MH084659 (C.W.L.). P.M.G.-B. acknowledge support from the Vanderbilt International Scholar Program (VISP).

ABBREVIATIONS USED

mGlu₁	metabotropic glutamate receptor subtype 1
nsSNP	nonsynonymous single nucleotide polymorphism
DMPK	drug metabolism and pharmacokinetics
PAM	positive allosteric modulator
NAM	negative allosteric modulator
Glu	glutamate

References

1. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. *Annu Rev Pharmacol Toxicol.* 1997; 37:205–237. [PubMed: 9131252]
2. Owen DR. Recent advances in the medicinal chemistry of the metabotropic glutamate receptor 1 (mGlu1). *ACS Chem Neurosci.* 2011; 2:394–401. [PubMed: 22860168]
3. Urwyler S. Allosteric modulation of Family C G-Protein-Coupled receptors: from molecular insights to therapeutic perspectives. *Pharmacol Rev.* 2011; 63:59–126. [PubMed: 21228259]
4. Emery AC, DiRaddo JO, Miller E, Hathaway HA, Pshenichkin S, Takoudjou GR, Grajkowska E, Yasuda RP, Wolfe BB, Wroblewski JT. Ligand bias at metabotropic glutamate 1a receptors: molecular determinants that distinguish β -arrestin-mediated from G protein-mediated signaling. *Mol Pharmacol.* 2012; 82:291–301. [PubMed: 22584219]
5. Engers DW, Lindsley CW. Allosteric modulation of Class C GPCRs: A novel approach for the treatment of CNS disorders. *Drug Discovery Today: Technol.* 2013; 10:e269–e276.
6. Lindsley CW. 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: Drug discovery targeting allosteric sites. *J Med Chem.* 2014; 57:7485–7498. [PubMed: 25180768]
7. Conn PJ, Lindsley CW, Meiler J, Niswender CM. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for the treatment of CNS disorders. *Nat Rev Drug Discovery.* 2014; 13:692–708. [PubMed: 25176435]
8. Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW. Drugs for allosteric sites on receptors. *Annu Rev Pharmacol Toxicol.* 2014; 54:165–184. [PubMed: 24111540]
9. Conn PJ, Lindsley CW, Jones C. Allosteric modulation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. *Trends Pharmacol Sci.* 2009; 30:25–31. [PubMed: 19058862]
10. Stauffer SR. Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5). *ACS Chem Neurosci.* 2011; 2:450–470. [PubMed: 22860171]
11. Lindsley CW, Stauffer SR. Metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs) for the treatment of schizophrenia: An historical perspective and a review of the patent literature. *Pharm Pat Anal.* 2013; 2:93–108. [PubMed: 24236973]
12. Emmittle KA. Recent advances in the design and development of novel negative allosteric modulators of mGlu5. *ACS Chem Neurosci.* 2011; 2:411–432. [PubMed: 21927649]
13. Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, Wichmann J, Kemp JA. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action and binding site. *Proc Natl Acad Sci U S A.* 2001; 98:13402–13407. [PubMed: 11606768]
14. Vieira E, Huwyler J, Jolidon S, Knoflach F, Mutel V, Wichmann J. 9*H*-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl and (2*H*-tertazol-5-yl)-amides as potent, orally available mGlu1 enhancers. *Bioorg Med Chem Lett.* 2005; 15:4628–4631. [PubMed: 16099654]
15. Vieira E, Huwyler J, Jolidon S, Knoflach F, Mutel V, Wichmann J. Fluorinated 9*H*-Xanthene-9-carboxylic acid oxazol-2-yl amides as potent, orally available mGlu1 enhancers. *Bioorg Med Chem Lett.* 2009; 19:1666–1669. [PubMed: 19233648]
16. Hemstapat K, dePaulis T, Chen Y, Brady AE, Grover VK, Alagille D, Tamagnan GD, Conn PJ. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. *Mol Pharmacol.* 2006; 70:616–626. [PubMed: 16645124]
17. Fazio F, Notartomaso S, Aronica E, Storto M, Battaglia G, Vieira E, Gatti S, Bruno V, Biagioni F, Gradini R, Nicoletti F, Di Marco R. Switch in the expression of mGlu1 and mGlu5 metabotropic glutamate receptors in the cerebellum of mice developing experimental autoimmune encephalomyelitis and in autaptic cerebellar samples from patients with multiple sclerosis. *Neuropharmacology.* 2008; 55:491–499. [PubMed: 18619983]
18. Ngomba RT, Santolini I, Biagioni F, Molinaro G, Simonyi A, van Rijn CM, D'Amore V, Mastroiacovo F, Olivieri G, Gradini R, Ferraguti F, Battaglia G, Bruno V, Puliti A, van Luitelaar G, Nicoletti F. Protective role for type-1 metabotropic glutamate receptors against spike and wave discharges in the WAG/Rij model of absence epilepsy. *Neuropharmacology.* 2011; 60:1281–1291. [PubMed: 21277877]

19. D'Amore V, Santolini I, Celli R, Lionetto L, De Fusco A, Simmaco M, van Rijn CM, Vieira E, Stauffer SR, Conn PJ, Bosco P, Nicoletti F, van Luijcklaar G, Ngomba RT. Head-to-head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats. *Neuropharmacology*. 2014; 85:91–103. [PubMed: 24859611]
20. Notartomaso S, Zappulla C, Biagioni F, Cannella M, Bucci D, Mascio G, Scarselli P, Fazio F, Weisz F, Lionetto L, Simmaco M, Gradini R, Battaglia G, Signore M, Puliti A, Nicoletti F. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. *Mol Brain*. 2013; 6:48. [PubMed: 24252411]
21. Frank RAW, McRae AF, Pocklington AJ, van de Lagemaat LN, Navarro P, Croning MDR, Komiyama NH, Bradley SJ, Challiss RAJ, Armstrong JD, Finn RD, Malloy MP, MacLean AW, Harris SE, Starr JM, Bhaskar SS, Howard EK, Hunt SE, Coffey AJ, Ranganath V, Deloukas P, Rogers J, Muir WJ, Deary IJ, Blackwood DH, Visscher PM, Grant SGN. Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder. *PLoS One*. 2011; 6:e19011. [PubMed: 21559497]
22. Ayoub MA, Angelicheva D, Vile D, Chandler D, Morar B, Cavanaugh JA, Visscher PM, Jablensky A, Pfleger KDG, Kalaydjieva L. Deleterious *GRM1* mutations in schizophrenia. *PLoS One*. 2012; 7:e32849. [PubMed: 22448230]
23. Cho HP, Garcia-Barrantes PM, Brogan JT, Hopkins CR, Niswender CM, Rodriguez AL, Venable D, Morrison RD, Bubser M, Daniels JS, Jones CK, Conn PJ, Lindsley CW. Chemical modulation of mutant mGlu₁ receptors derived from deleterious *GRM1* mutations found in schizophrenics. *ACS Chem Biol*. 2014; 9:2334–2346. [PubMed: 25137254]
24. Cho HP, Engers DW, Venable DF, Niswender CM, Lindsley CW, Conn PJ, Emmitte KA, Rodriguez AL. A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between rat and human receptors'. *ACS Chem Neurosci*. 2014; 5:597–610. [PubMed: 24798819]
25. Sharma S, Kedrowski J, Rook JM, Smith JM, Jones CK, Rodriguez AL, Conn PJ, Lindsley CW. Discovery of molecular switches that modulate modes of mGluR5 pharmacology *in vitro* and *in vivo* within a series of functionalized 5-(phenylethynyl)pyrimidines. *J Med Chem*. 2009; 52:4103–4106. [PubMed: 19537763]
26. Wood MR, Hopkins CR, Brogan JT, Conn PJ, Lindsley CW. 'Molecular switches' on allosteric ligands that modulate modes of pharmacology. *Biochemistry*. 2011; 50:2403–2410. [PubMed: 21341760]
27. Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA. Allosteric modulation for the treatment of schizophrenia: Targeting glutamatergic networks. *Curr Top Med Chem*. 2013; 13:26–54. [PubMed: 23409764]
28. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, Lindsley CW. Allosteric modulation of 7 transmembrane spanning receptors: Theory, practice and opportunities for CNS drug discovery. *J Med Chem*. 2012; 55:1445–1464. [PubMed: 22148748]
29. Bubser M, Bridges TM, Dencker D, Gould RW, Grannan M, Noetzel MJ, Niswender CM, Daniels JS, Melancon BJ, Tarr JC, Wess J, Duggan ME, Brandon NJ, Dunlop J, Wood MW, Wood MR, Lindsley CW, Conn PJ, Jones CK. Selective activation of M₄ muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. *ACS Chem Neurosci*. 2014; 5:920–942. [PubMed: 25137629]
30. Conde-Ceide S, Martin-Martin ML, Alcazar J, Manka T, Tong HM, Garcia-Barrantes PM, Lavreysen H, Mackie C, Vinson PN, Daniels SJ, Menges A, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Bartolome-Nebreda JM, Lindsley CW. Discovery of VU0409551/JNJ-46778212: An mGlu₅ positive allosteric modulator clinical candidate targeting schizophrenia. *ACS Med Chem Lett*. 2015; 6:716–720. [PubMed: 26157544]
31. Rook JM, Xiang Z, Lv X, Ghosal A, Dickerson J, Bridges TM, Johnson KA, Bubser M, Gregory KJ, Vinson PN, Byun N, Stauffer SR, Daniels JS, Niswender CM, Lavreysen H, Mackie C, Conde-Ceide S, Alcazar J, Bartolome JM, Macdonald GJ, Steckler T, Jones CK, Lindsley CW, Conn PJ. Biased mGlu₅ positive allosteric modulators provide *in vivo* efficacy without potentiating mGlu₅ modulation of NMDAR currents. *Neuron*. 2015; 86:1029–1040. [PubMed: 25937172]

32. Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: comparison between a positive allosteric modulator and an orthosteric agonist. *Neuropharmacology*. 2015; 95:121–129. [PubMed: 25749357]
33. Rook JM, Tantawy MN, Ansari MS, Felts AS, Stauffer SR, Emmitte KA, Kessler RM, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. *Neuropsychopharmacology*. 2015; 40:755–765. [PubMed: 25241804]
34. Morris LC, Nance KD, Gentry PR, Days EL, Weaver CD, Niswender CM, Thompson AD, Jones CK, Locuson CW, Morrison RD, Daniels JS, Niswender KD, Lindsley CW. Discovery of (*S*)-2-cyclopentyl-*N*-((1-isopropylpyrrolidin-2-yl)-9-methyl-1-oxo-2,9-dihydro-1*H*-pyrrolo[3,4-*b*]indole-4-carboxamide (VU0453379): a novel, CNS penetrant GLP-1 positive allosteric modulator (PAM). *J Med Chem*. 2014; 57:10192–10197. [PubMed: 25423411]
35. Byun NE, Grannan M, Bubser M, Barry RL, Thompson A, Rosanelli J, Gowrishankar R, Kelm ND, Damon S, Bridges TM, Melancon BJ, Tarr JC, Brogan JT, Avison MJ, Deutch AY, Wess J, Wood MR, Lindsley CW, Gore JC, Conn PJ, Jones CK. Antipsychotic drug-like effects of the selective M₄ muscarinic acetylcholine receptor positive allosteric modulator VU0152100. *Neuropsychopharmacology*. 2014; 39:1578–1593. [PubMed: 24442096]
36. Jones CK, Bubser M, Thompson AD, Dickerson JW, Blobaum AL, Bridges TM, Morrison RD, Daniels SJ, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM. The mGlu₄ positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine A_{2A} antagonist in preclinical rodent models of Parkinson's disease. *J Pharmacol Exp Ther*. 2012; 340:404–421. [PubMed: 22088953]
37. Williams R, Zhou Y, Niswender CM, Luo Q, Conn PJ, Lindsley CW, Hopkins CR. Re-exploration of the PHCCC scaffold: Discovery of improved positive allosteric modulators of mGluR4. *ACS Chem Neurosci*. 2010; 1:411–419. [PubMed: 20582156]
38. Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R, Daniels JS, Morrison R, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR. Discovery, synthesis, and development of a series of *n*-4-(2,5-dioxypyrrolidin-1-yl)-phenylpicolinamides: characterization of VU0195 (ML182) as a centrally active positive allosteric modulator of metabotropic glutamate receptor 4 (mGlu₄) with oral efficacy in an anti-parkinsonian animal model. *J Med Chem*. 2011; 54:7639–7647. [PubMed: 21966889]
39. See Supporting Information.
40. Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, Parton A, Kim-Kang H, Surapaneni S, Kumar G. Absorption, metabolism and excretion of [¹⁴C]pomalidomide in humans following oral administration. *Cancer Chemother Pharmacol*. 2013; 71:489–501. [PubMed: 23203815]
41. Barbosa MLD, Ramos TJF, de Arantes ACS, Martins MA, e Silva PMR, Barreiro EJ, Lima LM. Synthesis and pharmacological evaluation of novel phenyl sulfonamide derivatives designed as modulators of pulmonary inflammatory response. *Molecules*. 2012; 17:14651–14672. [PubMed: 23222927]
42. Tizzano JP, Griffey KI, Schoepp DD. Receptor subtypes linked to metabotropic glutamate receptor agonist-mediated limbic seizures in mice. *Ann N Y Acad Sci*. 1995; 765:230–241. [PubMed: 7486609]
43. Wong RK, Bianchi R, Chuang SC, Merlin LR. Group I mGluR-induced epileptogenesis: distinct and overlapping roles of mGlu1 and mGlu5 and implications for antiepileptic drug design. *Epilepsy Curr*. 2005; 5:63–74. [PubMed: 16059439]
44. Rook JM, Noetzel MJ, Pouliot WA, Bridges TM, Vinson PN, Cho HP, Zhou Y, Gogliotti RD, Manka JT, Gregory KJ, Stauffer SR, Dudek FE, Xiang Z, Niswender CM, Daniels JS, Jones JK, Lindsley CW, Conn PJ. Unique signaling profiles of positive allosteric modulators of mGlu₅ determine differences in in vivo activity. *Biol Psychiatry*. 2013; 73:501–509. [PubMed: 23140665]

45. Turlington ML, Noetzel MJ, Chun A, Zhou Y, Gogliotti RD, Nguyen ED, Gregory KJ, Vinson PN, Rook JM, Gogi KK, Xiang Z, Bridges TM, Daniels JS, Jones CK, Niswender CM, Meiler J, Conn PJ, Lindsley CW, Stauffer SR. Exploration of allosteric agonism structure-activity-relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu₅) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-*N*-(3-methyloxetan-3-yl)picolinamide (ML254). *J Med Chem.* 2013; 56:7976–7996. [PubMed: 24050755]
46. Noetzel MJ, Rook JM, Vinson PN, Cho KP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, Niswender CM, Xiang Z, Daniels JS, Lindsley CW, Weaver CD, Conn PJ. Functional impact of allosteric agonist activity of selective allosteric modulators of mGlu₅ in regulating CNS function. *Mol Pharmacol.* 2012; 81:120–133. [PubMed: 22021324]
47. Bridges TM, Rook JM, Noetzel MJ, Morrison RD, Zhou Y, Gogliotti RD, Vinson PN, Jones CK, Niswender CM, Lindsley CW, Stauffer SR, Conn PJ, Daniels JS. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizures in rats involving a receptor agonism-dependent mechanism. *Drug Metab Dispos.* 2013; 41:1703–1714. [PubMed: 23821185]

Figure 1.

Structure of the known mGlu₁ PAMs **1–5**, upon which target validation and therapeutic potential have been based. mGlu₁ PAMs **1–3** were the first described, but only **2** and **5** are active at both rat and human mGlu₁. In addition to pronounced species differences, all possessed poor physicochemical and DMPK properties, which limited their utility as in vivo proof of concept tool compounds.

Figure 2.

Second generation mGlu₁ PAM **8**, derived from a series of “molecular switches”, converting a highly selective mGlu₄ PAM **6** into an mGlu₁ NAM **7** and then, with limited optimization, conversion into a selective mGlu₁ PAM with comparable activity at human, rat, and mutant mGlu₁ receptors.

Figure 3. Optimization plans for mGlu₁ PAM **8** to enhance potency, stability, and CNS penetration via analogs **9**.

Figure 4.

All three mGlu₁ PAMs (**17d**, **17e**, and **17g**) are equipotent and equiefficacious on human and rat mGlu₁ WT receptors. (A) Concentration–response curves (CRCs) on human mGlu₁ WT receptors: **17d**, mGlu₁ EC₅₀ = 80.9 nM, pEC₅₀ = 7.09 ± 0.10, 94 ± 9% Glu Max; **17e**, mGlu₁ EC₅₀ = 31.8 nM, pEC₅₀ = 7.49 ± 0.15, 98 ± 6% Glu Max; and **17g** mGlu₁ EC₅₀ = 98.8 nM, pEC₅₀ = 7.01 ± 0.08, 94 ± 4% Glu Max. (B) Concentration–response curves (CRCs) on rat mGlu₁ WT receptors: **17d**, mGlu₁ EC₅₀ = 113 nM, pEC₅₀ = 6.95 ± 0.13, 107 ± 4% Glu Max; **17e**, mGlu₁ EC₅₀ = 40.7 nM, pEC₅₀ = 7.39 ± 0.18, 103 ± 5% Glu Max; and **17g** mGlu₁ EC₅₀ = 113 nM, pEC₅₀ = 6.95 ± 0.15, 115 ± 5% Glu Max.

Figure 5.

All three mGlu₁ PAMs induce a concentration-dependent, parallel leftward shift of the glutamate concentration–response curve (CRC) in cells expressing the human mGlu₁ WT receptor. (A) **17d** induces a ~8.3-fold shift, with modest (<20%) agonism noted at the 10 μ M concentration. (B) **17e** induces a ~11.4-fold shift, with noted (~35%) agonism at the 10 μ M concentration, and (C) **17g** induces a ~10.9-fold shift, with modest (<20%) agonism noted at the 10 μ M concentration. Thus, all three are more accurately described as mGlu₁ ago-PAMs in this assay.

Figure 6.

Ex vivo metabolism of **17d** in rat and human plasma. Upon incubation in either rat or human plasma at 37 °C, parent **17d** is exclusive species at $t = 0$, but by 4 h, no parent remains. Hydrolysis of the phthalimide moiety is complete in both rat and human plasma by 4 h, providing the regioisomeric phthalamic acids **M1** and **M2** as major metabolites, as well as the minor **M3**, the product of amide hydrolysis of **M1** and **M2**.

Figure 7.

Cartoon representation of monomeric of human mGlu₁, indicating nine of the nonsynonymous single nucleotide polymorphisms (nsSNPs) in the mGlu₁ receptor found in schizophrenic patients. Circled in blue are the four single point points in this study, three in the transmembrane domain (P729T, A863E, Y632H), and one in the intracellular, C-terminal domain (P1014S).

Figure 8.

All three mGlu₁ PAMs **17d**, **17e**, and **17g** induce a parallel leftward shift of the glutamate concentration–response–curve (CRC) in cells stably expressing human mGlu₁ mutant receptors (P729T (A), A683E (B), Y632H (C), P1014S(D)) found in schizophrenics. As in WT human mGlu₁ receptors, ago-PAM activity is noted, with **17e** showing robust ago-PAM activity across the four schizophrenia mutants evaluated.

Figure 9.

mGlu1 ago-PAM **17e** does not induce epileptiform activity in CA3 region of the hippocampus. (A) Sample traces of extracellular recordings from CA3 pyramidal cell body layer in hippocampal slices in control, during application and after washout of 10 μM **17e** (A1) and 50 μM DHPG (A2). (B) Average time courses of frequency of spontaneous activity before, during, and after application of **17e** ($n = 6$) and DHPG ($n = 6$), respectively. The gray bar indicates the time point at which the data were taken to make statistical comparison to the control levels. (C) Bar graphs summarizing the effects of 10 μM **17e** (left) and 50 μM DHPG (right) on the frequency of spontaneous activity in CA3 region of the hippocampus: (n.s.) $p = 0.36$; (**) $p = 0.0084$; paired t test.

Figure 10.

Metabotropic glutamate receptor subtype 1 positive allosteric modulators do not induce behavioral convulsions in mice. Severe, dose-dependent behavioral convulsions were observed in mice administered the mGlu₅ ago-PAM **18** (1 and 3 mg/kg, 10% Tween 80, 10 mL/kg) beginning 5 min following intraperitoneal dosing as measured by the modified Racine scale. In contrast, mGlu₁ ago-PAMs/PAMs **5**, **17d**, **17e**, and **17g** induce no adverse effects in mice at doses that reach brain concentration significantly higher than the compound's EC₅₀ at mGlu₁ (100 mg/kg, 10% Tween 80, 10 mL/kg). As two distinct mGlu₁ PAM chemotypes afford the same effect, confidence is high that mGlu₁ differentiates from mGlu₅ adverse effect liability. Data represent the mean $\pm$ SEM, $n = 3$.

Scheme 1. General Synthetic Route to Access mGlu₁ PAMs 9, 10, and 17^a

^aReagents and conditions: (a) phthalic anhydride, AcOH, reflux, 88%; (b) SnCl₂, HCl, dioxane, rt, 72%; (c) RCO₂H or substituted furylcarboxylic acids, HATU, DIEA, DCM, rt, 43–96%; (d) 3-methyl-2-furanyl chloride, DIEA, DCE, microwave 120 °C, 30 min, 97%; (e) SnCl₂, HCl, dioxane, rt, 96%; (f) phthalic anhydrides, AcOH, reflux, 34–92%.

Table 1Structures and Activities for Selected Five-Membered Heterocyclic Amides **9**

9				
Compd.	R	hmGlu ₁ EC ₅₀ (μM) ^a	pEC ₅₀ (±SEM) ^a	% Glu Max (±SEM) ^a
9a		0.55	6.26±0.10	76±6
9b		>10.0	>5.00	-
9c		>10.0	>5.00	-
9d		>10.0	>5.00	-
9e		>10.0	>5.00	-
9f		>10.0	>5.00	-
9g		>10.0	>5.00	-
9h		4.47	5.35±0.10	107±7

9				
Compd.	R	hmGlu ₁ EC ₅₀ (μM) ^a	pEC ₅₀ (±SEM) ^a	% Glu Max (±SEM) ^a
9i		>10.0	>5.00	-
9j		>10.0	>5.00	-
9k		>10.0	>5.00	-
9l		>10.0	>5.00	-
9m		>10.0	>5.00	39±4
9n		>10.0	>5.00	-

^a Calcium mobilization mGlu₁ assays. Values are average of three ($n = 3$) independent experiments performed in triplicate.

Table 2

Structures and Activities for Selected Furylamides 10

10				
Compd.	Furyl	hmGlu ₁ EC ₅₀ (μM) ^a	pEC ₅₀ (±SEM) ^a	% Glu Max (±SEM) ^a
10a		>10.0	>5.00	60±7
10b		>10.0	>5.00	30±4
10c		>10.0	>5.00	-
10d		>10.0	>5.00	55±3
10e		>10.0	>5.00	45±4
10f		>10.0	>5.00	43±6
10g		>10.0	>5.00	-
10h		>10.0	>5.00	35±3
10i		>10.0	>5.00	30±4

10				
Compd.	Furyl	hmGlu ₁ EC ₅₀ (μM) ^a	pEC ₅₀ (±SEM) ^a	% Glu Max (±SEM) ^a
10j		>0.097	7.01±0.15	118±3
10k		>10.0	>5.00	-
10l		>10.0	>5.00	-
10m		>10.0	>5.00	-
10n		>10.0	>5.00	-

^aCalcium mobilization mGlu₁ assays. Values are average of three ($n = 3$) independent experiments performed in triplicate.

Table 3

Structures and Activities for Selected 3-Methyl-2-furylcarboxamide Analogs 17

compd	R	hmGlu ₁ EC ₅₀ (nM) ^a	pEC ₅₀ (±SEM) ^a	% Glu Max (±SEM) ^a	hmGlu ₄ EC ₅₀ (nM) ^a	pEC ₅₀ (±SEM) ^a	% Glu Max ^b (±SEM) ^a	fold selective vs mGlu ₄
17a	3-Me	24.3	7.61 ± 0.16	86 ± 3	620	6.21 ± 0.18	153 ± 11	25.5
17b	4-Me	54.4	7.26 ± 0.21	86 ± 5	323	6.49 ± 0.26	69 ± 6	5.9
17c	3-Cl	33.0	7.48 ± 0.32	91 ± 6	1140	5.94 ± 0.22	163 ± 22	34.5
17d	4-Cl	80.9	7.09 ± 0.10	94 ± 9	2250	5.64 ± 0.11	89 ± 5	27.8
17e	3-F	31.8	7.49 ± 0.15	98 ± 6	1110	5.95 ± 0.16	122 ± 14	34.9
17f	4-F	24.1	7.62 ± 0.07	88 ± 3	712	6.14 ± 0.30	97 ± 7	29.7
17g	4-Aza	98.8	7.01 ± 0.08	94 ± 4	>10 000	>5.00	18 ± 4	>100

^a Calcium mobilization mGlu₁ assays. Values are average of three (*n* = 3) independent experiments performed in triplicate.^b Glu Max is expressed as % of PHCCC response.

Table 4

DMPK Characterization of mGlu₁ PAMs 5, 8, 17d, 17e, and 17g

parameter	5	8	17d	17e	17g
human CL _{INT} (mL min ⁻¹ kg ⁻¹)	262	17.2	2.90	3.10	167
human CL _{HEP} (mL min ⁻¹ kg ⁻¹)	19.4	9.46	2.54	2.70	18.6
rat CL _{INT} (mL min ⁻¹ kg ⁻¹)	661	39.9	22.8	207	405
rat CL _{HEP} (mL min ⁻¹ kg ⁻¹)	63.3	9.46	17.2	52.3	59.7
human <i>f_u</i> plasma	0.014	unstable	unstable	0.051	unstable
rat <i>f_u</i> plasma	0.003	unstable	unstable	0.030	0.030
CYP450 IC ₅₀ (μM)					
1A2	13	>30	>30	25.2	>30
2C9	0.6	>30	>30	6.45	>30
2D6	>30	>30	>30	>30	>30
3A4	>30	>30	>30	>30	>30
rat iv PK (0.2 mg/kg)					
<i>t</i> _{1/2} (min)	54	ND	91.1	53.6	5.38
MRT (min)	50	ND	53.5	64.1	7.85
CL _p (mL min ⁻¹ kg ⁻¹)	35	ND	33.0	13.3	382
<i>V_s</i> (L/kg)	1.34	ND	1.76	0.85	3.00
rat iv PBL (0.25 h, 0.2 mg/kg)					
<i>C_n</i> plasma (ng/mL)	276	336	173	200	12.5
<i>C_n</i> brain (ng/mL)	81	284	108	204	35.2
<i>K_p</i>	0.29	0.84	0.63	1.02	2.81

^aND, not determined.